Scholar Rock announces option exercised by Janssen in immuno-oncology collaboration focused on supracellular activation
Company generates unique monoclonal antibodies that selectively inhibit the supracellular activation of latent TGF-beta 1 in the immune system.
Scholar Rock has announced that Janssen Biotech has exercised an option as part of the existing immuno-oncology modulator collaboration. Scholar Rock’s successful generation of antibodies that selectively inhibit the supracellular activation of the growth factor TGF-beta 1 in the immune system by targeting its supracellular activation represents a novel approach in immuno-oncology therapeutics, and triggered the decision.
Under the terms of the original collaboration agreement, facilitated by Johnson & Johnson Innovation and announced in January 2014, Scholar Rock granted Janssen options to obtain worldwide exclusive licenses to pursue development and commercialization of supracellular activation targeted therapeutics intended to selectively modulate TGF-beta 1 activation in the immune system.
“Starting with a novel pharmacological hypothesis, within two short years we have been able to discover drug candidates that represent a unique immuno-oncology opportunity,” said Nagesh Mahanthappa, President and CEO of Scholar Rock. “This key milestone, taken together with our own nomination this past September of SRK-015 as our first proprietary development candidate for the treatment of muscle diseases, clearly demonstrates the power and productivity of our supracellular activation platform.”
“Our foundation of Scholar Rock stemmed from unique structural biology insights into how growth factors are activated or kept latent in vivo that suggested novel therapeutic modalities. Indeed, Scholar Rock’s preclinical data suggests that disease can be treated earlier than previously thought possible, at the step before harmful growth factors are released. Moreover, we have now achieved this for two different growth factor programs, one proprietary and the other in our collaboration with Janssen,” said Timothy A. Springer, co-founder of Scholar Rock and Latham Family Professor at Harvard Medical School and Professor of Medicine at Children’s Hospital Boston. “Scholar Rock’s innovative supracellular activation platform is well on its way toward generating an entirely new class of therapeutics with novel mechanisms of action.”
The research collaboration between Scholar Rock and Janssen has been conceived to focus on the discovery and development of novel antibody therapeutics that modulate supracellular activation, and thereby selectively inhibit TGF-beta 1 in the immune system for immuno-oncology applications, or selectively activate TGF-beta 1 in the immune system for the treatment of autoimmune diseases. The collaboration between Scholar Rock and Janssen to identify supracellular activation targeted therapeutics for the treatment of autoimmune diseases is continuing.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance